Skip to main content
MedPathMedPath Home
Clinical Trials/ISRCTN18000901
ISRCTN18000901
Active, not recruiting
未知

The iDiabetes Platform: enhanced phenotyping of patients with diabetes for precision diagnosis, prognosis and treatment

niversity of Dundee0 sites22,500 target enrollmentMarch 5, 2024
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsDiabetesNutritional, Metabolic, Endocrine

Overview

Phase
未知
Intervention
Not specified
Conditions
Diabetes
Sponsor
niversity of Dundee
Enrollment
22500
Status
Active, not recruiting
Last Updated
last year
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
March 5, 2024
End Date
June 30, 2026
Last Updated
last year
Study Type
Interventional
Sex
All

Investigators

Sponsor
niversity of Dundee

Eligibility Criteria

Inclusion Criteria

  • •1\. Registered patients with a diagnosis of diabetes
  • •2\. Age \>18 years

Exclusion Criteria

  • •Does not meet the inclusion criteria

Outcomes

Primary Outcomes

Not specified

Similar Trials

Recruiting
Not Applicable
Diabetes Mellitus Management using Ayurveda
CTRI/2023/07/054665Sri Sarada Ayurveda Hospital
Active, not recruiting
Phase 1
Prevention of diabetes in very young children (age 4 to 7 month) at high genetic risk for type 1 diabetes with oral insulin therapy
EUCTR2017-003088-36-PLTechnische Universität München, Represented by the school of medicine1,040
Active, not recruiting
Phase 1
Prevention of diabetes in very young children (age 4 to 7 month) at high genetic risk for type 1 diabetes with oral insulin therapyrisk for type 1 diabetesMedDRA version: 21.1Level: PTClassification code 10066284Term: Diabetes prophylaxisSystem Organ Class: 10042613 - Surgical and medical proceduresTherapeutic area: Diseases [C] - Immune System Diseases [C20]
EUCTR2017-003088-36-DETechnische Universität München, Represented by the school of medicine1,040
Active, not recruiting
Phase 1
Prevention of diabetes in very young children (age 4 to 7 month) at high genetic risk for type 1 diabetes with oral insulin therapy
EUCTR2017-003088-36-BETechnische Universität München, Represented by the school of medicine1,040
Active, not recruiting
Phase 1
Prevention of diabetes in very young children (age 4 to 7 month) at high genetic risk for type 1 diabetes with oral insulin therapy
EUCTR2017-003088-36-SETechnische Universität München, Represented by the school of medicine1,040